GlassScriptPhysician profile
Ashton Kyle Newman
NPI 1578341459
$1,884.24
in general payments reported to CMS, 2019-2025
23 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $45.47 · 2024: $773 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $371.60 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $185.22 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.05 | 2025 | |
| Lilly USA, LLC | $131.77 | 2024-2025 | Mounjaro, Zepbound |
| Amgen INC. | $108.91 | 2024-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $103.99 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Corcept Therapeutics | $94.10 | 2025 | Korlym |
| Pfizer INC. | $90.81 | 2024-2025 | |
| Averitas Pharma INC. | $88.55 | 2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $73.73 | 2024-2025 | |
| Glaxosmithkline, LLC. | $63.78 | 2023-2025 | Trelegy Ellipta, Shingrix, Boostrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.65 | 2024-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $45.54 | 2024 | Quviviq |
| Lundbeck LLC | $45.05 | 2024 | Vyepti |
| Shield Therapeutics INC | $41.42 | 2023-2024 | Accrufer |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.65 | 2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $35.14 | 2024-2025 | Voquezna |
| Medtronic, INC. | $32.90 | 2024-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $24.18 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $23.59 | 2025 | Capvaxive, Gardasil 9 |
| Inspire Medical Systems, INC. | $20.22 | 2025 | Inspire |
| Ultragenyx Pharmaceutical INC. | $18.00 | 2024 | Crysvita |
| Exact Sciences Corporation | $14.39 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashton Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.